In order to expedite Pfizer and Moderna’s permits in India, the government may provide them a crucial concession: indemnity from liability.
Other countries have done so, according to Health Ministry sources, and “providing indemnity or legal protection from any disputes related to the use of a company’s COVID-19 vaccine” is “no problem.”
“If these companies have applied for Emergency Use Authorisation in India, then we are ready to give them indemnity,” the sources said.
The pharma authority has also waived the requirement for India-specific trials for imported vaccinations licenced for emergency use by certain nations and the WHO. If international businesses have received approval to conduct “post-launch bridging trials” and assess the quality and stability of their vaccines in India, the Drug Controller General of India (DCGI) has waived the requirement from specific countries or health bodies.
Despite these concessions, Pfizer and Moderna will take time to join India’s vaccine programme because to the high demand for Covid shots around the world. Pfizer enjoys protection in countries such as the United States, meaning it cannot be sued for any side effects. So far, India has refused to indemnify any producer against the price of compensation for serious adverse effects.